CV | Ticker Profile - Titan Protect

CapsoVision, Inc.

Healthcare · Medical Devices · NCM

$7.19

Data: 2026-05-15

✓ ETHICAL PASS

MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$323M

Total market value of the company

Trailing P/E

N/A

Forward P/E

N/A

Based on estimated future earnings — lower means cheaper

Rev Growth

+13.5%

Year-over-year revenue change

Profit Margin

-186.8%

How much profit the company keeps from each dollar of revenue

ROE

-184.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$10.00

+39% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 1 analysts covering this stock

About CapsoVision, Inc.

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.

https://capsovision.com

Country: United States Employees: 99 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.2% PASS

Debt must be below 33% of total assets

Cash Ratio

2.8% PASS

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

1.184

Excellent risk-adjusted returns

Kelly Fraction

0.0855

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.527

Returns exceed worst-case losses — strong risk profile

Annual Return

103.5%

Historical annualised return based on price data

Max Drawdown

-67.8%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$15.37

53% below the year high

52W Low

$3.43

109% above the year low

Avg Volume

290,822

Average daily shares traded — higher means easier to buy and sell

Short Ratio

9.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

3.8%

Low short interest — limited bearish positioning

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.03

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.07

Conservative use of debt — low financial risk

Current Ratio

3.77

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

2.85

Like current ratio but excludes inventory — stricter test

Gross Margin

52.9%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-186.4%

Profit from core operations before interest and tax

Free Cash Flow

$-13,007,125

Negative — the business is spending more than it generates

Revenue (TTM)

$14M

Total revenue over the last 12 months

Net Income

$-25,315,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$10.00

Target Median

$10.00

Target Low

$10.00

Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date	Insider	Title	Shares	Value
2026-05-05	ATKINSON DOUGLAS PATRICK	Officer	107,357	$44,692
2025-12-31	GOUW JULIA S	Director	2,887	$30,862
2025-12-31	IMPERIAL JOANNE CAROL M.D.	Director	2,887	$30,862
2025-12-31	KUO HUI YING	Director	2,887	$30,862
2025-12-31	KING WEN-HERNG HENRY	Director	2,887	$30,862
2025-12-31	TSAI CHEN LUNG	Director	2,887	$30,862
2025-12-31	HARARI MICHELE	Director	2,887	$30,862
2025-08-18	PETERSEN REBECCA ANN	Officer	24,834	$9,097
2025-07-03	HARARI ELIYAHOU ET AL	Beneficial Owner of more than 10% of a Class of Security	4,222,422	—
2025-07-03	KUO HUI YING	Director	10,354	—

Source: SEC Form 4 filings via public data. View all insider activity at

Insider Intelligence

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
7 Feb2025	Tim Walberg	Republican	buy	15K–50K
24 Apr2026	Jonathan Jackson	Democrat	sell	50K–100K
2026-04-13	Ro Khanna	Democrat	Purchase	1K–15K
2026-04-13	Ro Khanna	Democrat	Purchase	1K–15K
2025-11-21	Dwight Evans	Democrat	Sale	1K–15K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Before you go